Sélectionner une page
Logo Company

Alaxia

Philippe BORDEAU

VP Innovation & Business Development

Who are we?

ALAXIA and its partner Stragen develop innovative therapeutics ALX-009 and STR-324. ALX-009 is a first-in-class antimicrobial wide spectrum product targeting to kills bacteria including antibiotic resistant strains and to compensate deficient innate lung defense system in Cystic Fibrosis. Other than the killing properties, the potential of ALX-009 resides in its particular mode of action not generating resistance. Clinical trial with CF patients is currently ongoing. STR-324 is a first-in-class non-opioid painkiller with a safe, non-addictive and innovative mode of action DENKI based for various pain indications including neuropathic pain. Clinical trial is currently ongoing.